Prix SymBio Pharmaceuticals Limited (SYMQY)

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 108 full-time employees. The company went IPO on 2011-10-20. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The firm develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The firm manufactures and sells medicines through domestic and foreign pharmaceutical companies. The firm's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.